论文部分内容阅读
Dugmore和Ra(?)hand曾报导3例患玻璃体出血病人,在玻璃体内注射尿激酶以后视力改善,Forresfer和Williamoson也报导了相似的结果,并认为这种治疗方法比玻璃体切除来得优越,作者用猴进行实验研究、观察: 1.玻璃体内注射尿激酶对眼组织的毒性。 2.确定在玻璃体内注射尿激酶的无毒性剂量,并估价尿激酶对早期、晚期以及反复玻璃体出血的治疗效果。把实验猴分为四组: 第一组4只分别注射尿激酶11,250、22,500、33,750和67,500CTA单位0.2ml于双眼玻璃体内,另一只注射生理盐水作对照。每次注射前均
Dugmore and Rahand have reported 3 patients with vitreous hemorrhage who improved visual acuity after intravitreal injection of urokinase and Forresfer and Williamoson also reported similar results and considered this treatment superior to vitrectomy. Monkey experimental study, observation: 1. Intravitreal injection of urokinase on ocular tissue toxicity. 2. To determine the non-toxic dose of urokinase injected into the vitreous, and evaluate the therapeutic effect of urokinase on early, late, and repeated vitreous hemorrhage. The experimental group was divided into four groups: the first group of 4 were injected urokinase 11,250,22,500,33,750 and 67,500CTA unit 0.2ml in the binocular vitreous, the other injection of normal saline as a control. Before each injection